Vertex Pharmaceuticals dans l'actualité
Développement de médicaments transformateurs
Tamtam a trouvé 20 articles récents sur Vertex Pharmaceuticals.
- Has Vertex Stock Become A Different Bet?
- Vertex Pharmaceuticals falls 2.94% in Thursday's session
- 2 Growth Stocks to Buy in November Without Any Hesitation
- At $547.86 apiece, a director sold 271 Vertex Pharmaceuticals (VRTX) shares.
- Genomics and Vertex Extend $220 million Drug Discovery Partnership Deal
- After selling 1,000 shares of Vertex Pharmaceuticals (VRTX), Nancy Thornberry directly held 1,109.
- Vertex Pharmaceuticals stock gains EUR 485.85, up 0.65%
- Vertex Pharmaceuticals (VRTX) Stock May Be Undervalued After Its 187% Run
- Should You Pick Vertex Stock Over Its Biotech Rivals?
- VRTX Stock News Today: Latest Updates & Live Price | MEXC
- VRTX: Pivotal renal readouts and expanding non-CF revenue shape the 2027 outlook
- Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loom
- Vertex at Jefferies Global Healthcare Conference: kidney push builds
- Vertex Pharmaceuticals stock slips to EUR 487.60, down 1.28%
- Will Vertex Pharmaceuticals (NASDAQ:VRTX) Turn Its Pipeline Into Momentum?
- Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms
- Director Sangeeta N. Bhatia proposes selling 271 Vertex Pharmaceuticals (VRTX) shares.
- Vertex Pharmaceuticals stock at EUR 492.55, up 1.10%
- Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom
- Vertex Pharmaceuticals stock: Management's UBS conference appearance
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Vertex Pharmaceuticals ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires